Calcium antagonists in dermatology: A review of the evidence and research-based studies

Dermatology Online Journal

Volumn 11, Issue 2, 2005, Pages

  Palamaras, Ioulios ^a   Kyriakos, Kyriakis ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CALCIUM ANTAGONIST; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; COLLAGEN; DILTIAZEM; EFONIDIPINE; FELODIPINE; FIBRONECTIN; GALLOPAMIL; ISRADIPINE; LACIDIPINE; LIDOCAINE; MANIDIPINE; NICARDIPINE; NIFEDIPINE; NIMODIPINE; NISOLDIPINE; NITRENDIPINE; PROTEOGLYCAN; SCLEROPROTEIN; SUPEROXIDE; VERAPAMIL;

ANALGESIA; ANTIHYPERTENSIVE ACTIVITY; ANUS FISSURE; ANUS PRURITUS; BURN SCAR; CELL ADHESION; CELL GROWTH; CELL PROLIFERATION; CLINICAL TRIAL; COLD INJURY; CONSTIPATION; DERMATITIS; DIPLOPIA; DISEASE EXACERBATION; DIZZINESS; DRUG ACTIVITY; DRUG ERUPTION; ERYTHROMELALGIA; EXPERIMENTAL MODEL; FIBROBLAST; FLUSHING; GINGIVA HYPERPLASIA; GROWTH INHIBITION; GYNECOMASTIA; HEADACHE; HEART MUSCLE; HUMAN; IMMUNOMODULATION; INHIBITION KINETICS; IONTOPHORESIS; KELOID; LUPUS ERYTHEMATOSUS; LYMPHOCYTE; MAST CELL DEGRANULATION; MOUTH ULCER; NEUROTRANSMITTER RELEASE; NEUTROPHIL; NONHUMAN; ORTHOSTATIC HYPOTENSION; PEMPHIGOID; PERIPHERAL EDEMA; PHAGOCYTOSIS; PHOTOSENSITIVITY; POSTHERPETIC NEURALGIA; POTASSIUM TRANSPORT; PSORIASIS; RAYNAUD PHENOMENON; REVIEW; SCLERODERMA; SIDE EFFECT; SKIN CALCIFICATION; SKIN DISEASE; SKIN NECROSIS; SYNDROME CREST; T LYMPHOCYTE ACTIVATION; TACHYCARDIA; TELANGIECTASIA; THROMBOCYTE AGGREGATION; TREATMENT INDICATION; VASCULAR SMOOTH MUSCLE; VASODILATATION;

EID: 24044482936     PISSN: 10872108     EISSN: 10872108     Source Type: Journal    
DOI: None     Document Type: Review

References (101)

1. Abernethy D, Schwartz J, Calcium-Antagonists Drugs, N Engl J Med 341 (19):1447-1457, 1999
2. Flynn J, Pasko D, Calcium channel blockers: pharmacology and place in therapy of pediatric hypertension, Pediatr Nephrol. 15:302-316, 2000
3. Luscher T, Cosentino F, The classification of calcium antagonists and their selection in the treatment of hypertension A Reappraisal, Drugs. Vol 55(4):509-517, 1998
4. Stepien O, Zhang Y, Zhu D, Marche PDual mechanism of action of amlodipine in human vascular smooth muscle cells, J Hypertens. 2002 Jan;20(1):95-102
5. Eickelberg O, Roth M, Block LH. Effects of amlodipine on gene expression and extracellular matrix formation in human vascular smooth muscle cells and fibroblasts: implications for vascular protection. Int J Cardiol. 1997 Dec 31;62 Suppl 2:S31-7
6. Wada Y, Kato S, Okamoto K et al. Diltiazem, a calcium antagonist, inhibits matrix metalloproteinase-1 (tissue collagenase) production and collagenolytic activity in human vascular smooth muscle cells, Int J Mol Med. 2001 Nov;8 (5):561-6
7. Zeitler H, Ko Y, Glodny B et al. Cell-cycle arrest in G0/G1 phase of growth factor-induced endothelial cell proliferation by various calcium channel blockers. Cancer Detect Prev. 1997;21(4):332-9.
8. Roth M, Eickelberg O, Kohler E et al. Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix, Proc Natl Acad Sci USA 1996 May 28;93(11):5478-82.
9. Lee RC, Ping JA. Calcium antagonists retard extracellular matrix production in connective tissue equivalent, J Surg Res 1990 Nov;49(5):463-6
10. Roth M, Eickelberg O, Kohler E et al. Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix, Proc Natl Acad Sci USA 1996 May 28;93(11):5478-82.
11. Huang S, Maher VM, McCormick J. Involvement of intermediary metabolites in the pathway of extracellular Ca2+-induced mitogen-activated protein kinase activation in human fibroblasts, Cell Signal. 1999 Apr;11(4):263-74
12. Kang Y, Lee DA, Higginbotham EJ, In vitro evaluation of antiproliferative potential of calcium channel blockers in human Tenon's fibroblasts. Exp Eye Res. 1997 Jun;64(6):913-25
13. Doong H, Dissanayake S, Gowrishankar TR et al. The 1996 Lindberg Award. Calcium antagonists alter cell shape and induce procollagenase synthesis in keloid and normal human dermal fibroblasts. J Burn Care Rehabil. 1996 Nov-Dec;17(6 Pt1):497-514
14. D'Andrea F, Brongo S, Ferraro G et al. Prevention and treatment of keloids with intralesional verapamil, Dermatology. 2002;204(1):60-2.
15. Magro CM, Crowson AN, Drug-induced immune dysregulation as a cause of atypical cutaneous lymphoid infiltrates: a hypothesis, Hum Pathol. 27(2):125-32, 1996
16. Derenne F, Vanhaeverbeek M, Brohee D. Nifedipine-induced hyporeactivity in delayed hypersensitivity skin tests, Int J Immunopharmacol. 1987;9(6):741-4
17. Weinzweig N, Lukash F, Weinzweig J, Topical and systemic calcium channel blockers in the prevention and treatment of microvascular spasm in a rat epigastric island skin flap model, Ann Plast Surg 1999;42:320-326
18. Takahara K, Kuroiwa A, Matsushima T et al. Effects of nifedipine on platelet function, Am Heart J 1985 Jan;109(1):4-8
19. Wolfram RM, Kritz H, Oguogho A et al. Antiplatelet activity of semotiadil fumarate, Thromb Res. 2002 May 15;106(4-5):187-90
20. Knight CJ, Panesar M, Wilson DJ et al. Different effects of calcium antagonists, nitrates, and beta-blockers on platelet function. Possible importance for the treatment of unstable angina. Circulation. 1997 Jan 7;95(1):125-32
21. Hernandez-Hernandez R, Armas-Padilla MC, Velasco M et al. Effects of amlodipine and enalapril on platelet function in patients with mild to moderate hypertension. Int J Clin Pharmacol Ther. 1999 Jul;37(7):323-31
22. Sanguigni V, Gallu M, Sciarra L et al. Effect of amlodipine on exerciseinduced platelet activation in patients affected by chronic stable angina. Clin Cardiol. 1999 Sep;22(9):575-80.
23. Winther K, Gleerup G, Hedner T, Platelet function and fibrinolytic activity in hypertension: differential effects of calcium antagonists and beta-adrenergic receptor blockers, J Cardiovasc Pharmacol. 1991;18 Suppl 9:S41-4
24. Smith A, McPherson J, Taylor M et al. Pro-haemorrhagic effects of calcium antagonists: a comparison of isradipine and atenolol on ex vivo platelet function in hypertensive subjects, J Hum Hypertens 1997 Dec;11(12):783-8
25. Ranieri G, Filitti V, Andriani A et al. Effects of isradipine sustained release on platelet function and fibrinolysis in essential hypertensives with or without other risk factors. Cardiovasc Drugs Ther. 1996 May;10(2):119-23.
26. O'Grady J, Kritz H, Schmid P et al. Effect of isradipine on in-vivo platelet function, Thromb Res. 1997 Jun 1;86(5):363-71
27. Tison P, Ulicna L, Jakubovska Z et al. Effects of dihydropyridines and their combination with aspirin on blood pressure and circadian platelet activity in patients with essential hypertension. Am J Hypertens. 1994 Jul;7(7 Pt 2):46S-49S.
28. Tschoepe D, Homberg M, Roesen P et al. Reduced platelet thromboxane formation after long-term administration of a dihydropyridine calcium channel blocker: a prospective, double-blind, placebo-controlled study with nitrendipine in borderline hypertensive patients with IDDM-type diabetes mellitus, Diabetes Res. 1992 Mar;19(3):125-31
29. Feinberg WM, Bruck DC, Effect of oral nimodipine on platelet function Stroke. 1993 Jan;24(1):10-3.
30. Armas-Padilla MC, Armas-Hernandez MJ, Hernandez-Hernandez R et al. Effect of lacidipine and nifedipine GITS on platelet function in patients with essential hypertension. J Hum Hypertens. 2000 Apr;14 Suppl 1:S91-5
31. Fujinishi A, Takahara K, Ohba C et al. Effects of nisoldipine on cytosolic calcium, platelet aggregation, and coagulation/fibrinolysis in patients with coronary artery disease. Angiology. 1997 Jun;48(6):515-21
32. Nomura S, Kanazawa S, Fukuhara S, Effects of efonidipine on platelet and monocyte activation markers in hypertensive patients with and without type 2 diabetes mellitus. J Hum Hypertens. 2002 Aug;16(8):539-47
33. Tomiyama H, Kimura Y, Kuwabara Y, Cilnidipine more highly attenuates cold pressor stress-induced platelet activation in hypertension than does amlodipine, Hypertens Res. 2001 Nov;24(6):679-84
34. Shen YC, Chen CF, Wang SY et al. Impediment to calcium influx and reactive oxygen production accounts for the inhibition of neutrophil Mac-1 Up-regulation and adhesion by tetrandrine, Mol Pharmacol. 1999 Jan;55(1):186-93.
35. Khalfi F, Gressier B, Dine T, Verapamil inhibits elastase release and superoxide anion production in human neutrophils, Biol Pharm Bull. 1998 Feb;21 (2):109-12
36. Haga Y, Dumitrescu A, Zhang Y et al. p.o. Effects of calcium blockers on the cytosolic calcium, H2O2 production and elastase release in human neutrophils. Pharmacol Toxicol. 1996 Dec;79(6):312-7.
37. Feng YH, Hart G, Suppression of oxidant production by diltiazem, nifedipine and verapamil in human neutrophils, Clin Sci (Lond). 1996 Oct;91(4):459-66.
38. Levy R, Dana R, Gold B, Influence of calcium channel blockers on polymorphonuclear and monocyte bactericidal and fungicidal activity, Isr J Med Sci. 1991 Jun;27(6):301-6
39. Kazanjian PH, Pennington JE, Influence of drugs that block calcium channels on the microbicidal function of human neutrophils, J Infect Dis. 1985 Jan;151 (1):15-22
40. Rosales C, Brown EJ, Calcium channel blockers nifedipine and diltiazem inhibit Ca2+ release from intracellular stores in neutrophils, J Biol Chem. 1992 Jan 25;267(3):1443-8.
41. Filep JG, Foldes-Filep E, Inhibition by calcium channel blockers of the binding of platelet-activating factor to human neutrophil granulocytes, Eur J Pharmacol. 1990 Nov 6;190(1-2):67-73
42. Irita K, Fujita I et al. Calcium channel antagonist induced inhibition of superoxide production in human neutrophils. Mechanisms independent of antagonizing calcium influx, Biochem Pharmacol. 1986 Oct 15;35(20):3465-71
43. Levy R, Nagauker-Shriker O, Schlaeffer F, Inhibited neutrophil functions in patients treated with nifedipine but not with verapamil or diltiazem, Eur J Clin Invest. 1996 May;26(5):376-81
44. Neumann FJ, Ott I et al. Effect of gallopamil on neutrophil function: experimental and clinical studies, J Cardiovasc Pharmacol. 1992;20 Suppl 7:S21-5.
45. Taniguchi K, Miyagawa A, MIzutani A et al, The effect of calcium channel antagonist administered by iontophoresis on pain threshold, Acta Anaesthesiol Belg 46(2):69-73, 1995
46. Doering CJ, Zamponi GW, Molecular pharmacology of high voltage-activated calcium channels, J Bioenerg Biomembr. 2003 Dec;35(6):491-505
47. Wallace MS, Calcium and sodium channel antagonists for the treatment of pain, Clin J Pain. 2000 Jun;16(2 Suppl):S80-5.
48. Snutch TP, Sutton KG, Zamponi GW, Voltage-dependent calcium channels-beyond dihydropyridine antagonists, Curr Opin Pharmacol. 2001 Feb;1(1):11-6
49. Ioulios P, Charalampos M, Efrossini T, The spectrum of cutaneous reactions associated with calcium antagonists: a review of the literature and the possible etiopathogenic mechanisms, Dermatol Online J. 2003 Dec;9(5):6
50. Sturgill MG, Seibold JR, Rational use of calcium-channel antagonists in Raynaud's phenomenon, Curr Opin Rheumatol 10(6):584-8, 1998
51. No authors listed, Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1-year follow up, Arch Intern Med 160(8):1101-8, 2000
52. Rodeheffer RJ, Rommer JA, Wigley F, Smith CR, Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon, N Engl J Med 1983 Apr 14;308(15):880-3
53. Smith CD, McKendry RJ, Controlled trial of nifedipine in the treatment of Raynaud's phenomenon, Lancet 1982 Dec 11;2(8311):1299-301
54. Sauza J, Kraus A, Gonzalez-Amaro R, Alarcon-Segovia D, Effect of the calcium blocker nifedipine on Raynaud's phenomenon. A controlled double blind trial, J Rheumatol 1984 Jun;11(3):362-4
55. Kallenberg CG, Wouda AA, Kuitert JJ et al. Nifedipine in Raynaud's phenomenon: relationship between immediate, short term and long term effects, J Rheumatol 1987 Apr;14(2):284-90
56. Sarkozi J, Bookman AA, Mahon W et al. Nifedipine in the treatment of idiopathic Raynaud's syndrome, J Rheunatol 1986 Apr;13(2):331-6
57. La Civita L, Pitaro N, Rossi M et al. Amlodipine in the treatment of Raynaud's phenomenon, Br J Rheumatol 1993 Jun;32(6):524-5
58. Belch JJ, Ho M, Pharmacotherapy of Raynaud's phenomenon Drugs, 1996 Nov;52(5):682-95
59. Kahan A, Amor B, Menkes CJ, A Randomized double-blind trial of diltiazem in the treatment of Raynaud's phenomenon, Ann Rheum Dis 1985 Jan;44(1):30-3
60. Kallenberg CG, Wouda AA, Meems L et al. Once daily felodipine in patients with primary Raynaud's phenomenon, Eur J Clin Pharmacol 1991;40(3):313-5
61. Gjorup T, Hartling OJ, Kelbaek H, Nielsen SL, Controlled double-blind trial of nisoldipine in the treatment of idiopathic Raynaud's phenomenon, Eur J Clin Pharmacol 1986;31(4):387-9
62. Leppert J, Jonasson T, Nilsson H, Ringqvist I, The effect of isradipine, a new calcium-channel antagonist, in patients with primary Raynaud's phenomenon: a single-blind dose-response study, Cardiovasc Drugs Ther 1989 Jun;3(3):397-401
63. Wigley FM, Wise RA, Malamet R, Scott TE, Nicardipine in the treatment of Raynaud's phenomenon. Dissociation of platelet activation from vasospasm, Arthritis Rheum 1987 Mar;30(3):281-6
64. Ferri C, Cecchetti R, Cini G et al. Slow-releasing nicardipine in the treatment of Raynaud's phenomena without underlying Clin Rheumatol. 1992 Mar;11(1):76-80
65. No authors listed, Controlled multicenter double-blind trial of nicardipine in the treatment of primary Raynaud phenomenon. French Cooperative Multicenter Group for Raynaud Phenomenon, Paris, France Am Heart J. 1991 Jul;122(1 Pt2):352-5.
66. Wollersheim H, Thien T Double-blind placebo-controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. J Cardiovasc Pharmacol. 1991 Dec;18(6):813-8.
67. Kahan A, Amor B, Menkes CJ et al. Nicardipine in the treatment of Raynaud's phenomenon: a randomized double-blind trial, Angiology 1987 Apr;38(4):333-7
68. Excerpted from: Treatment of Raynaud's phenomenon I, UpToDate® 2002
69. Excerpted from: Treatment of Raynaud's phenomenon II, UpToDate® 2002
70. Excerpted from: Treatment of Scleroderma-I, UpToDate® 2002
71. Thompson AE, Shea B, Welch V et al. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis, Artritis Rheum 2001 Aug;44 (8):1841-7
72. Lisse J, Raynaud phenomenon in: www.emedicine.com
73. Nifedipine: Drug information handbook, UpToDate® 2002
74. Wise RA, Malamet R, Wigley FM, Acute effects of nifedipine on digital blood flow in human subjects with Raynaud's phenomenon: a double blind placebo controlled trial, J Rheumatol 1987 Apr;14(2):278-83
75. Agaoglu N, Cengiz S, Arslan MK et al. Oral nifedipine in the treatment of chronic anal fissure Dig Surg. 2003;20(5):452-6. Epub 2003 Jul 31
76. Nisoldipine, British National Formulary 47, March 2004, pag:106
77. Takahara K, Kuroiwa A, Matsushima T et al. Effects of nifedipine on platelet function, Am Heart J 1985 Jan;109(1):4-8
78. Wolfram RM, Kritz H, Oguogho A et al. Antiplatelet activity of semotiadil fumarate, Thromb Res. 2002 May 15;106(4-5):187-90
79. Rustin MH, Newton JA, Smith NP et al. The treatment of chilblains with nifedipine: the results of a pilot study, a double-blind placebo-controlled randomized study and a long-term open trial. Br J Dermatol. 1989 Feb;120(2):267-75.
80. Cribier B, Chilblain, Ann Dermatol Venereol. 2001 Apr;128(4):557-60
81. Agaoglu N, Cengiz S, Arslan MK et al. Oral nifedipine in the treatment of chronic anal fissure Dig Surg. 2003;20(5):452-6. Epub 2003 Jul 31
82. Cook TA, Humphreys MM, McC Mortensen NJ, Oral nifedipine reduces resting anal pressure and heals chronic anal fissure. Br J Surg. 1999 Oct;86 (10):1269-73
83. Ezri T, Susmallian S. Topical nifedipine vs. topical glyceryl trinitrate for treatment of chronic anal fissureDis Colon Rectum. 2003 Jun;46(6):805-8
84. Carapeti EA, Kamm MA, Phillips RK, Topical diltiazem and bethanechol decrease anal sphincter pressure and heal anal fissures without side effects, Dis Colon Rectum 2000 Oct;43(10):1359-62
85. Jonas M, Neal KR, Abercrombie JF et al. A randomized trial of oral vs. topical diltiazem for chronic anal fissures Dis Colon Rectum 2001 Aug;44(8):1074-8
86. Knight JS, Birks M, Farouk R Topical diltiazem ointment in the treatment of chronic anal fissure Br J Surg. 2001 Apr;88(4):553-6.
87. Griffin N, Acheson AG, Jonas M et al. The role of topical diltiazem in the treatment of chronic anal fissures that have failed glyceryl trinitrate therapy. Colorectal Dis. 2002 Nov;4(6):430-5.
88. Bielecki K, Kolodziejczak M A prospective randomized trial of diltiazem and glyceryl trinitrate ointment in the treatment of chronic anal fissure. Colorectal Dis. 2003 May;5(3):256-7.
89. Jonas M, Speake W, Scholefield JH, Diltiazem heals glyceryl trinitrateresistant chronic anal fissures: a prospective study. Dis Colon Rectum. 2002 Aug;45(8):1091-5
90. Ansaloni L, Bernabe A, Ghetti R et al. Oral lacidipine in the treatment of anal fissure. Tech Coloproctol. 2002 Sep;6(2):79-82.
91. Nelson R, Treatment of anal fissure, BMJ 2003;327:354-55 (16 August)
92. Utzig MJ, Kroesen AJ, Buhr HJ, Concepts in pathogenesis and treatment of chronic anal fissure - a review of the literature, Am J Gastroenterol. 2003 May;98 (5):968-74
93. Minguez M, Herreros B, Benages A, Chronic Anal Fissure. Curr Treat Options Gastroenterol. 2003 Jun;6(3):257-262.
94. Bhardwaj R, Vaizey CJ, Boulos PB et al. Neuromyogenic properties of the internal anal sphincter: therapeutic rationale for anal fissures. Gut. 2000 Jun;46 (6):861-8.
95. Chrysos E, Xynos E, Tzovaras G et al. Effect of nifedipine on rectoanal motility, Dis Colon Rectum. 1996 Feb;39(2):212-6.
96. Perrotti P, Bove A, Antropoli C et al. Topical nifedipine with lidocaine ointment vs. active control for treatment of chronic anal fissure: results of a prospective, randomized, double-blind study. Dis Colon Rectum. 2002 Nov;45 (11):1468-75
97. Palmieri GM et al, Treatment of calcinosis with diltiazem, Arthritis Rheum 38 (11):1646-54, 1995
98. Nunley J, Jones L, Calcinosis cutis in: www.emedicine.com
99. Komorowska-Timek E, Chen S, Zhang F et al. Prolonged perivascular use of verapamil or lidocaine decreases skin flap necrosis, Ann Plast Surg 1999;43:283-288
100. Björn Stark G, Dorer A, Jaeger K et al. The influence of the calcium blocker nimodipine on flap survival, Ann Plast Surg;23:306-9, 1989
101. Kawabata H, Kenneth K, Serena C et al. Experience with calcium antagonists nitrendipine, diltiazem and verapamil and b2-agonist salbutamol in salvaging ischemic skin flaps in rabbits, Microsurgery 12:160-3, 1991